FLOT1 and neoplasm: However, the FLOT1 HR subgroup exhibited significantly lower 5-year OS rates than the FLOT1 LR subgroup among patients with advanced tumor stages (38.6% vs. 51.6% at 5 years, P = 0.00944; Supplementary Fig. 3B).